HK Stock Market Move | HANSOH PHARMA (03692) rises nearly 4%; median OS for recanlifutotug reached 18.5 months.

HANSOH PHARMA (03692) rose nearly 4%, up 3.73% as of press time, at HK$33.94, with a turnover of HK$205 million. On the news front, on September 13, HANSOH PHARMA presented the interim results of the Phase III ARTEMIS-008 study of its self-developed B7-H3-targeting ADC, recanlifutotug (HS-20093), in an oral presentation as a late-breaking abstract at the first Presidential Forum of the 2026 World Conference on Lung Cancer. According to the data released this time, recanlifutotug set a new record for the longest overall survival (OS) in second-line treatment of small cell lung cancer (SCLC). Specifically, the median OS for recanlifutotug reached 18.5 months, compared with 10.3 months for topotecan. Jefferies believes it is confident in the potential best-in-class (BIC) profile of Ris-Rez and that it is expected to further expand into earlier-line treatment. JPMorgan pointed out that it maintains an "Overweight" rating on HANSOH PHARMA with a target price of HK$50, and forecasts that its innovative drug sales and licensing revenue will drive revenue and earnings CAGR of 12% and 15% respectively from 2020 to 2030. Potential future catalysts include sales of commercialized drugs, key data readouts for late-stage assets, and additional out-licensing transactions.